Recombinant Hemagglutinin and Virus-Like Particle Vaccines for H7N9 Influenza Virus.
Recombinant Hemagglutinin and Virus-Like Particle Vaccines for H7N9 Influenza Virus.
复制标题
DOI：
10.4172/2157-7560.1000287
复制
发表时间：
2015-06
期刊：
影响因子：
--
通讯作者：
Xiaohui Li;P. Pushko;I. Tretyakova
中科院分区：
文献类型：
--
作者：
Xiaohui Li;P. Pushko;I. Tretyakova
H7N9人类感染病例是由2013年在中国东部出现的一种新型禽源性H7N9甲型流感病毒引起的。在中国的许多城市发现了人类疾病的集群，死亡率接近30%。由于历史上流感大流行是由新型甲型流感病毒引入免疫学未成熟人群引起的，因此引起了大流行的担忧。目前，还没有针对H7N9病毒的获批人类疫苗。重组蛋白疫苗方法在安全性和可制造性方面具有优势。在这篇综述中，我们重点评估了重组血凝素（rHA）蛋白作为H7N9流感候选疫苗的表达，重点是寡聚体和颗粒结构在免疫原性和保护中的作用。广泛的保护性流感疫苗的制备中的挑战进行了讨论，并提出了广泛的保护性疫苗的例子，包括rHA干表位疫苗，以及最近推出的实验性多HA VLP疫苗。
Cases of H7N9 human infection were caused by a novel, avian-origin H7N9 influenza A virus that emerged in eastern China in 2013. Clusters of human disease were identified in many cities in China, with mortality rates approaching 30%. Pandemic concerns were raised, as historically, influenza pandemics were caused by introduction of novel influenza A viruses into immunologically naïve human population. Currently, there are no approved human vaccines for H7N9 viruses. Recombinant protein vaccine approaches have advantages in safety and manufacturing. In this review, we focused on evaluation of the expression of recombinant hemagglutinin (rHA) proteins as candidate vaccines for H7N9 influenza, with the emphasis on the role of oligomeric and particulate structures in immunogenicity and protection. Challenges in preparation of broadly protective influenza vaccines are discussed, and examples of broadly protective vaccines are presented including rHA stem epitope vaccines, as well as recently introduced experimental multi-HA VLP vaccines.